CRVS earnings analysis
What we found in CRVS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Corvus Pharmaceuticals reported Q1 2026 results, with a net loss of $13.7 million, maintaining an EPS of -$0.15, matching expectations but signaling continuous challenges given prior net income of $15.2 million in Q1 2025. The company still reported no revenue for the quarter, falling short of the estimated $620,000, despite a strengthened cash position anticipated to support operations until Q2 2028.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Cash Position Improved
- Corvus has cash, cash equivalents, and marketable securities totaling $236.7 million, expected to fund operations into Q2 2028.
- Increased R&D Spending
- Research and development expenses rose to $11.2 million from $7.5 million in the same quarter last year, reflecting ongoing trials.
- Safety and Efficacy Updates
- Soquelitinib has shown promising results in clinical trials for relapsed T cell lymphomas, with four patients achieving complete responses.
- Completed Financing
- The January 2026 follow-on offering generated approximately $189.4 million, bolstering liquidity.
- Strategic Trials Ongoing
- Active enrollment in Phase 3 trials for soquelitinib and Phase 2 trials for atopic dermatitis is progressing.
- Positive Regulatory Feedback
- The FDA granted Fast Track designation for soquelitinib in treating relapsed PTCL, indicating regulatory support.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Net Losses
- The company reports a net loss of $13.7 million for Q1 2026, contrasting sharply with a net income of $15.2 million in Q1 2025.
- No Revenue Generated
- Corvus has not generated any revenue in Q1 2026, missing the consensus estimate of $620,000.
- Heavy Reliance on External Financing
- The company has an accumulated deficit of $426 million, raising concerns about the sustainability of operations without further financing.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.15
What they said about what is next.
Current plans indicate sufficient cash to fund operations into Q2 2028.
The filing reads worse than the one before it.
What came before.
- 10-Q · November 12, 2024
- Corvus reported a Q3 net loss of $40,217,000 (loss per share $0.60) versus a loss of $6,000,000 (loss per share $0.12) in the year-ago quarter; the large quarter-over-quarter deterioration was driven primarily by a…
- 10-K · March 19, 2024
- Corvus Pharmaceuticals is a clinical-stage immunology-focused biotech advancing three clinical candidates (soquelitinib, ciforadenant, mupadolimab) with lead asset soquelitinib showing encouraging early activity and a…
- 10-Q · August 8, 2023
- Corvus reported improved operating trends in Q2 2023 with net loss narrowing to $(6,503)k (EPS $(0.14)) from $(8,363)k (EPS $(0.18)) in Q2 2022, driven by lower R&D and G&A. Cash and marketable securities totaled $37.0M…
- 10-K · March 10, 2022
- Corvus Pharmaceuticals remains focused on developing immune modulator product candidates for various cancers and diseases. The lead product, mupadolimab, has shown promising results in clinical trials, especially in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CRVS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever